| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/11/2006 | EP1613631A1 Pyrrolo 1,2-b pyridazine compounds and their uses |
| 01/11/2006 | EP1613630A1 Pyrrolo'1,2-b!pyridazine compounds and their use as crf1 receptor antagonists |
| 01/11/2006 | EP1613628A2 Reversible inhibitors of s-adenosyl-l-homocysteine hydrolase and uses thereof |
| 01/11/2006 | EP1613626A1 Cyclic benzimidazoles |
| 01/11/2006 | EP1613625A1 Novel fused triazolones and the uses thereof |
| 01/11/2006 | EP1613623A1 Novel oxazole derivatives, their manufacture and use as pharmaceutical agents |
| 01/11/2006 | EP1613622A1 Oxime derivatives and their use as pharmaceutically active agents |
| 01/11/2006 | EP1613621A1 Prostaglandin analogs as ep4 receptor agonists |
| 01/11/2006 | EP1613620A1 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| 01/11/2006 | EP1613617A2 Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5 |
| 01/11/2006 | EP1613612A2 Bioreductively-activated prodrugs |
| 01/11/2006 | EP1613606A2 Methods for preparing 2,3,5,6-substituted 3h-pyrimidin-4-ones |
| 01/11/2006 | EP1613603A2 Migrastatin analogs and uses thereof |
| 01/11/2006 | EP1613602A1 Alkylated iminodibenzyls as antioxidants |
| 01/11/2006 | EP1613601A2 Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists |
| 01/11/2006 | EP1613598A2 Methods of preparing aripiprazole crystalline forms |
| 01/11/2006 | EP1613597A1 6-substituted nicotinamide derivatives as opioid receptor antagonists |
| 01/11/2006 | EP1613595A2 Novel compounds and compositions as protein kinase inhibitors |
| 01/11/2006 | EP1613594A1 4-(2-phenylsulfanyl-phenyl)-1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors |
| 01/11/2006 | EP1613592A2 Hydroxamic acid compounds and methods of use thereof |
| 01/11/2006 | EP1613587A2 Organic compounds |
| 01/11/2006 | EP1613584A1 Highly pure bases of 3,3-diphenyl propylamine monoesters |
| 01/11/2006 | EP1613573A2 Production of 5-methyl-1-hydrocarbyl-2-pyrrolidone by reductive amination of levulinic acid |
| 01/11/2006 | EP1613385A1 Oxygen inhalation apparatus and method |
| 01/11/2006 | EP1613368A2 Carboxamide spirohydantoin cgrp receptor antagonists |
| 01/11/2006 | EP1613356A1 A fluoroquinolone aqueous formulation of a ph between 4 and 7 comprising i.a. cyclodextrin, hydroxy acid |
| 01/11/2006 | EP1613354A2 Improved penetration of active substances into cells and organs |
| 01/11/2006 | EP1613353A1 Pharmaceutical compositions for hepatitis c viral protease inhibitors |
| 01/11/2006 | EP1613342A1 Interferon beta in severe acute respiratory syndrome (sars) |
| 01/11/2006 | EP1613339A2 Anti-fungal peptidomimetics |
| 01/11/2006 | EP1613333A1 Oral extended release compressed tablets of multiparticulates |
| 01/11/2006 | EP1613332A2 Formulations for mediating inflammation and for reducing blood cholesterol |
| 01/11/2006 | EP1613331A1 Compositions containing lactulose for treating rotavirus infections |
| 01/11/2006 | EP1613330A1 Combination of a macrolide t-cell immunomodulator and a calciferol for the treatment of skin diseases or of inflammatory bowel disease |
| 01/11/2006 | EP1613329A1 Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders |
| 01/11/2006 | EP1613328A1 Use of carbamazepine derivatives for the treatment of agitation in dementia patients |
| 01/11/2006 | EP1613327A2 Pharmaceutical combination containing tamsulosin and a non-steroidal anti-inflammatory drug |
| 01/11/2006 | EP1613326A1 (3-{3-´(2,4-bis-trifluormethyl-benzyl)-(5-ethyl-pyrimidin-2-yl)-amino!-propoxy}-phenyl)-acetic acid and related compounds as modulators of ppars and methods of treating metabolic disorders |
| 01/11/2006 | EP1613325A1 Combinations comprising paroxetine and 2-(s)-(4-fluoro-2-methyl-phenyl)-piperazine-1-carboxylic acid [1-(r)-(3,5-bis-trifluoro-2-methyl-phenyl)-ethyl]-methyl amide for treatment of depression and/or anxiety |
| 01/11/2006 | EP1613324A2 Methods for the treatment of pain comprising opioid antagonists |
| 01/11/2006 | EP1613323A1 Pharmaceutical compositions comprising apomorhine for pulmonary inhalation |
| 01/11/2006 | EP1613322A2 Aminoquinoline compounds |
| 01/11/2006 | EP1613321A2 Muscarinic m1 receptor agonists for pain management |
| 01/11/2006 | EP1613320A1 Dosage forms comprising ag013736 |
| 01/11/2006 | EP1613319A2 Substituted phenyl acetamides and their use as protease inhibitors |
| 01/11/2006 | EP1613318A2 Compounds and their use to treat diabetes and related disorders |
| 01/11/2006 | EP1613317A1 Combination of a macrolide and a local anesthetic for the treatment of dermatological diseases |
| 01/11/2006 | EP1613316A1 Compositions comprising macrolide t-cell immunomodulators or immunosuppressants in combination with antibacterials |
| 01/11/2006 | EP1613314A1 Pharmaceutical composition comprising an immunosuppressant for use in the treatment of skin diseases |
| 01/11/2006 | EP1613313A1 2-phenyl-benzimidazol and 2-phenyl-imidazo-4,5!-pyridine derivatives as checkpoint kinase cds1 (chk2) inhibitors for the treatment of cancer |
| 01/11/2006 | EP1613311A2 Hif-1 inhibitors |
| 01/11/2006 | EP1613310A1 Imidazole derivatives for treatment of allergic and hyperproliferative disorders |
| 01/11/2006 | EP1613309A1 Use of atii antagonist for the treatment or prevention of metabolic syndrome |
| 01/11/2006 | EP1613308A1 Novel methods for the treatment of cancer |
| 01/11/2006 | EP1613307A2 M sb 3 /sb muscarinic acetylcholine receptor antagonists |
| 01/11/2006 | EP1613306A1 Decreasing the incidence of atrial fibrillation (af) in patients with left ventricular dysfunction with ace inhibitors or angiotensin ii receptor antagonists |
| 01/11/2006 | EP1613305A1 Crystalline n-formyl hydroxylamine compounds |
| 01/11/2006 | EP1613303A1 Substituted p-diaminobenzene derivatives |
| 01/11/2006 | EP1613302A2 Preserved and stable compositions containing peptide copper complexes and methods related thereto |
| 01/11/2006 | EP1613301A1 Use of l-carnitine for the treatment of cardiovascular diseases |
| 01/11/2006 | EP1613300A2 Photostabilized topical formulations of ketoprofen containing two uv filters |
| 01/11/2006 | EP1613299A2 Combination product for controlling insect pests |
| 01/11/2006 | EP1613298A2 Lysophosphatidic acid analogs and inhibition of neointima formation |
| 01/11/2006 | EP1613297A1 Therapeutic patch with polysiloxane matrix comprising capsaicin |
| 01/11/2006 | EP1613296A2 Methods for treatment of parkinson's disease |
| 01/11/2006 | EP1613295A1 Use of alkyl resorcinols in the treatment of acne |
| 01/11/2006 | EP1613293A1 Extended transdermal contraceptive regimens |
| 01/11/2006 | EP1613288A1 Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol |
| 01/11/2006 | EP1613287A1 Venlafaxine compositions comprising pellets with double layer coating |
| 01/11/2006 | EP1613284A2 Manufacturing process for liposomal preparations |
| 01/11/2006 | EP1613282A1 Formulations and methods for treating rhinosinusitis |
| 01/11/2006 | EP1613281A1 Nasal pharmaceutical formulations and methods of using the same |
| 01/11/2006 | EP1613280A1 Nasal pharmaceutical formulations and methods of using the same |
| 01/11/2006 | EP1613278A1 A topical agent containing niacin for application to the skin prior to luminous treatment |
| 01/11/2006 | EP1613276A1 Low viscosity liquid dosage forms |
| 01/11/2006 | EP1613271A2 Computer-based model for identification and characterization of non-competitive inhibitors of nicotinic acetylcholine receptors and related ligand-gated ion channel receptors |
| 01/11/2006 | EP1613270A2 Film forming polymers, methods of use, and devices and applications thereof |
| 01/11/2006 | EP1613269A2 Compositions, methods and kits relating to her-2 cleavage |
| 01/11/2006 | EP1613268A2 Methods for inhibition of angiogenesis |
| 01/11/2006 | EP1613267A2 Use of fgf- 18 protein, target proteins and their respective encoding nucleotide sequences to induce cartilage formation |
| 01/11/2006 | EP1613266A2 Methods of treating pain and compositions for use therefor |
| 01/11/2006 | EP1613265A2 Di-aryl substituted pyrrole modulators of metabotropic glutamate receptor-5 |
| 01/11/2006 | EP1613254A2 Alcohol-free transdermal analgesic composition and processes for manufacture and use thereof |
| 01/11/2006 | EP1613180A1 Synbiotic combination |
| 01/11/2006 | EP1613155A2 Treatment of demyelinating conditions |
| 01/11/2006 | EP1581172A4 Treatment of skin wounds using polyenylphosphatidylcholine and alkanolamines |
| 01/11/2006 | EP1534713B1 Alkyl-substituted pyrazolopyrimidines |
| 01/11/2006 | EP1525202B1 Novel 2,5-disubstituted pyrimidine derivatives |
| 01/11/2006 | EP1521761B1 Treatment of congenital disorders of glycosylation (cdg) using mannose |
| 01/11/2006 | EP1491206A4 Induction method for cell differentiation |
| 01/11/2006 | EP1469743A4 Stable hygroscopic compositions and methods for stabilizing hygroscopic ingredients |
| 01/11/2006 | EP1442036B1 Heteroaryl derivatives as superior ligands for nociceptin receptor orl-1 |
| 01/11/2006 | EP1442035B1 Process for the preparation of 4- (8-chloro-5, 6-dihydro-11h-benzo-[5,6]-cyclohepta-[1,2-b]-pyridin-11-ylidene)-1-piperidinecarboxylic acid ethyl ester (loratadine) |
| 01/11/2006 | EP1435986A4 Igf-binding protein-derived peptide or small molecule |
| 01/11/2006 | EP1421082B1 piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity |
| 01/11/2006 | EP1407033B1 Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva) |
| 01/11/2006 | EP1395572B1 Process for preparing a thiazole ppar-ligand and polymorphs thereof |
| 01/11/2006 | EP1385489B1 Coated granules based on angiotensin-converting enzyme inhibitor |
| 01/11/2006 | EP1370529B1 Substituted dimethyl- 1-(1-phenyl-cyclohexyl)-piperidin-3-yl methyl]-amines and the use of the same as analgesics |
| 01/11/2006 | EP1366036B1 Compounds having activity as inhibitors of cytochrome p450rai |